Companies
/Healthcare
Werewolf Therapeutics Inc
$0.98
▼ $0.01 (−0.66%) today
Markets closed · 11:39pm ET
Today · % change
Fundamentals
Market Cap
$48.0M
Profit Margin
-164.8%
Revenue (TTM)
$21.0M
EPS (TTM)
$-0.75
52-Week Range
$0 – $2
Street Target
$7.00
About Werewolf Therapeutics
Werewolf Therapeutics Inc is a pioneering biopharmaceutical firm focused on cancer treatment through innovative immune system stimulation. Utilizing its unique PREDATOR platform, the company creates molecules that activate only under specific conditions, aiming to overcome the challenges of traditional immune therapies. Its portfolio includes WTX-124 and WTX-330, both in early clinical trials targeting solid tumors and lymphoma, alongside other promising candidates for various cancers. Founded in 2017, Werewolf Therapeutics is based in Watertown, Massachusetts, leading the charge in next-generation cancer immunotherapy.